{"id":"anti-b-raf","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dermatitis"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2108949","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The B-Raf protein is a kinase that plays a key role in cell signaling pathways. Mutations in this protein can lead to uncontrolled cell growth and cancer. By inhibiting B-Raf, these drugs aim to slow or stop the growth of cancer cells.","oneSentence":"Anti-B-RAF drugs target and inhibit the B-Raf protein, which is often mutated in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:46.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma with a V600E mutation"},{"name":"Other cancers with B-Raf mutations"}]},"trialDetails":[{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT04585815","phase":"PHASE1, PHASE2","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT04800822","phase":"PHASE1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-03-17","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT05621525","phase":"PHASE1","title":"Phase I Study of the BBP-398 in Patients With Advance Solid Tumors","status":"TERMINATED","sponsor":"LianBio LLC","startDate":"2022-10-18","conditions":"Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT06362694","phase":"PHASE2","title":"Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-03-25","conditions":"Anaplastic Thyroid Cancer","enrollment":10},{"nctId":"NCT00378703","phase":"PHASE2","title":"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09-14","conditions":"Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7","enrollment":361},{"nctId":"NCT01878396","phase":"","title":"Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors","status":"UNKNOWN","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2011-12","conditions":"Metastatic Melanoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-B-RAF","genericName":"Anti-B-RAF","companyName":"Istituto Oncologico Veneto IRCCS","companyId":"istituto-oncologico-veneto-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-B-RAF drugs target and inhibit the B-Raf protein, which is often mutated in cancer cells. Used for Metastatic melanoma with a V600E mutation, Other cancers with B-Raf mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}